摘要
目的 评价司帕沙星对耐多药肺结核 (MDR -PTB)的疗效。方法 10 4例MDR -PTB患者随机分为两组 ,以氧氟沙星作为对照。治疗组 5 2例采用 3SHRZE +SPLX 9HRE +SPLX方案治疗 ,对照组采用 3SHRZE +OFLX 9HRE +OFLX方案治疗。结果 疗程结束时 ,治疗组痰菌阴转率 92 .3% ,明显高于对照组 69.2 % (P <0 .0 5 ) ;治疗 2个月时治疗组痰菌阴转阴率与对照组相比有显著性差异(P <0 .0 1)。结论 司帕沙星是目前氟喹诺酮类中治疗MDR -PTB较为有效的药物。
Objective To evaluate the therapeutic effect of sparfloxacin (SPLX)on multidrug resistant pulmonary tuberculosis (MDR-PTB).Methods 104 cases of MDR-PTB were allocated at random pair to two groups,using domestic ofloxacin (OFLX) as comparison.52 cases were treated with the regimen of 3SHRZE+SPLX/9HRE+SPLX.52 cases were treated with the regimen of 3SHRZE+OFLX/9HRE+OFLX.Results At the end of treatment,the sputum negative conversion rates of treatment group were 92.3%,while the rates of control group were 69.2%, P <0.05,after two months treatment the difference of the sputum negative conrersion rate in the treatment group was statistically significant when compared with the control group (P<0.01) .Conclusion Sparfloxacin is an effective drug in treating patients with MDR-PTB among other quinolones.
出处
《中国防痨杂志》
CAS
北大核心
2001年第5期308-310,共3页
Chinese Journal of Antituberculosis
